NASDAQ: TLXTelix Pharmaceuticals Ltd Stock
$17.40+0.04 (+0.23%)
Updated Apr 30, 2025
TLX Price
$17.40
Fair Value Price
N/A
Market Cap
$5.82B
52 Week Low
$13.61
52 Week High
$30.36
P/E
N/A
P/B
16.3x
P/S
11.12x
PEG
N/A
Dividend Yield
N/A
Revenue
$492.58M
Earnings
$31.01M
Gross Margin
65.1%
Operating Margin
11.87%
Profit Margin
6.4%
Debt to Equity
1.67
Operating Cash Flow
$27M
Beta
0.97
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
TLX Overview
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company offers Illuccix for the treatment of prostate cancer; and TLX66-CDx for the treatment of imaging osteomyelitis. Its products candidates include TLX591, a radio antibody-drug conjugate for the treatment of prostate cancer; TLX250-CDx for the treatment and diagnosis of renal (kidney) cancer; TLX101-CDx for brain (glioma) cancer; TLX66-CDx to treat bone marrow conditioning; TLX300-CDx for the treatment and diagnosis of soft tissue sarcoma; and TLX250 for the treatment of clear cell renal cell carcinoma. The company also develops TLX101 for the treatment of glioblastoma (brain cancer); TLX66 for the treatment of bone marrow conditioning; TLX300 for the treatment of soft tissue sarcoma; and TLX592, a prostate cancer therapy candidate for targeted alpha therapy. Telix Pharmaceuticals Limited was founded in 2015 and is headquartered in North Melbourne, Australia.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine TLX's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
TLX
Ranked#54 of 462
Ranked#54 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $3.07 | A | |
| $8.24 | A | |
| $24.29 | A |
Be the first to know about important TLX news, forecast changes, insider trades & much more!
TLX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how TLX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TLX is poor value based on its book value relative to its share price (16.3x), compared to the US Biotechnology industry average (4.45x)
P/B vs Industry Valuation
TLX's Earnings (EBIT) of $58.49M are insufficient to safely cover interest payments on company debt ($365.69M)
Interest Coverage Financials
TLX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
There are 30 more TLX due diligence checks available for Premium users.
Valuation
TLX fair value
Fair Value of TLX stock based on Discounted Cash Flow (DCF)
Price
$17.40
Fair Value
-$4.65
Undervalued by
474.13%
TLX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
16.3x
Industry
4.45x
TLX is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
TLX's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
TLX's Earnings (EBIT) of $58.49M... subscribe to Premium to read more.
Interest Coverage Financials
TLX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$941.9M
Liabilities
$589.0M
Debt to equity
1.67
TLX's short-term assets ($577.71M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TLX's short-term assets ($577.71M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TLX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
TLX's operating cash flow ($27.06M)... subscribe to Premium to read more.
Debt Coverage Financials
TLX vs Biotech Stocks
Telix Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.